AGT Partners

American Gene Technologies (AGT) is a clinical-stage biotechnology company specializing in the development of gene and cell therapies for infectious diseases, monogenic disorders, and cancer. The company utilizes a proprietary lentiviral platform to deliver genetic payloads that modify the immune system or correct genetic defects. Its lead candidate, AGT-103-T, is an autologous cell therapy currently in clinical trials aimed at providing a functional cure for HIV by protecting T cells from viral entry and replication. AGT is also advancing a pipeline of therapies for Phenylketonuria (PKU) and various solid tumors, leveraging its expertise in genetic medicine to address unmet medical needs. In 2023, the company launched Addimmune, a dedicated entity to focus on the commercialization and late-stage development of its HIV cure program. The company's approach combines advanced viral vector technology with innovative immunology to create durable treatments for complex diseases.